More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$744131259
EPS
-1.61
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.414259
Previous close
$7.22
Today's open
$7.20
Day's range
$7 - $7.31
52 week range
$4.73 - $9.54
show more
CEO
Elisabet de los
Employees
113
Headquarters
Boston, MA
Exchange
NASDAQ Global Market
Shares outstanding
104074302
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate
Oxford, UK – 17 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today confirm its manufacturing and supply partnership with Aura Biosciences, Inc. (“Aura”) (NASDAQ: AURA), a biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers. OXB is supporting late-stage development and manufacturing activities for Aura's lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar), as Aura advances the programme through Phase 3 development and prepares for potential future commercial supply. Aura recently announced the partnership and its manufacturing strategy in its Q3 corporate update.
GlobeNewsWire • Nov 17, 2026

Here's Why You Should Add AURA Stock to Your Portfolio Now
Aura completes phase III enrollment for bel-sar, with pivotal data expected in 2027 and additional ocular cancer programs expanding its growth potential.
Zacks Investment Research • Nov 12, 2026

Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 119.6% in Aura Biosciences (AURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Nov 11, 2026

Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar Early choroidal melanoma investor and analyst virtual event planned for December 8, 2026 Expected cash runway into 1H 2029 BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”) a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “During the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development,” said Natalie Holles, Chief Executive Officer of Aura Biosciences.
GlobeNewsWire • Nov 9, 2026

Aura Biosciences to Participate in Upcoming Investor Conference
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026. Fireside chat at 2:40 p.m.
GlobeNewsWire • Nov 3, 2026

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare
Aura Biosciences offers a de-risked, fully funded play on the bel-sar for early choroidal melanoma, with pivotal Phase 3 data expected in 2027. AURA's cash position of $323.8 million as of June 2026 supports operations into 1H 2029, eliminating near-term financing risk ahead of its binary readout. Strategic refocus on ocular oncology, leadership overhaul, and workforce reduction streamline execution and concentrate resources on a largely uncontested market.
Seeking Alpha • Oct 31, 2026

Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 16, 2026

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura's new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura's new Chief Operating Officer, and Julie Person, Aura's new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Sep 1, 2026

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.
Seeking Alpha • Aug 12, 2026

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.
GlobeNewsWire • Jul 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Aura Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.